剩余财产分配完毕后，本基金管理人将按照法律法规及相关规定办理本基金的账户注销等业务。投资人 可拨打本基金管理人的客户服务电话（400-700-8880）了解相关事宜。 华商基金管理有限公司 本基金自2025年12月20日至2025年12月29日期间进行了基金财产清算，基金财产清算报告报中国证监会 备案后，本基金管理人于2026年1月20日在本基金管理人网站（www.hsfund.com）和中国证监会基金电 子披露网站（http://eid.csrc.gov.cn/fund）刊登了《华商创新医疗混合型证券投资基金清算报告》（以下 简称"《清算报告》"）。根据《基金合同》的约定，《基金合同》终止日是指《基金合同》规定的《基 金合同》终止事由出现后，基金财产清算完毕，清算结果报中国证监会备案并予以公告的日期。据此， 本基金《基金合同》终止日为2026年1月20日。 根据《中华人民共和国证券投资基金法》《公开募集证券投资基金运作管理办法》《华商创新医疗混合 型证券投资基金基金合同（更新）》（以下简称"《基金合同》"）的有关规定，华商创新医疗混合型证 券投资基金（以下简称"本基金"）已出现触发《基金合同》终止的情形，华 ...

1月21日的资金流向数据方面，主力资金净流入3845.08万元，占总成交额3.3%，游资资金净流入 4050.81万元，占总成交额3.48%，散户资金净流出7895.88万元，占总成交额6.78%。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-21 | 28.37 | -0.14% | 3845.08万 | 3.30% | 4050.81万 | 3.48% | -7895.88万 | -6.78% | | 2026-01-20 | 28.41 | -3.20% | -9828.11万 | -7.33% | -4303.63万 | -3.21% | 1.41亿 | 10.54% | | 2026-01-19 | 29.35 | 0.51% | -9841.20万 | -6.09% | -2407.44万 | -1.49% | 1.22亿 | 7.58% | | 2026-01-16 | 29.20 | - ...

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Core Viewpoint - Xianjian Technology (01302) saw a significant increase in stock price, rising by 4.07% to HKD 1.79, with a trading volume of HKD 37.76 million following the approval of its innovative medical device by the National Medical Products Administration [1] Group 1: Product Approval - The Concave Supra integrated three-branch reconstruction system, co-developed by Professor Shu Chang from the National Center for Cardiovascular Diseases and Xianjian Technology, has been approved for entry into the special review process for innovative medical devices, known as the "green channel" for national innovation [1] - This marks the 17th product from Xianjian Technology to be approved for the national innovation "green channel," highlighting the company's commitment to research and development in the medical device sector [1] Group 2: Product Features - The CS stent system is designed for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, representing a global first in providing a solution for integrated three-branch reconstruction without brain ischemia [1] - The product will complement Xianjian's existing innovative product matrix for aortic arch branch reconstruction, including chimney technology and in-situ fenestration techniques, thereby offering a comprehensive solution for endovascular treatment of aortic arch lesions [1]

智通财经APP获悉，先健科技(01302)尾盘涨超4%，截至发稿，涨4.07%，报1.79港元，成交额3776.46万 港元。 公开资料显示，该产品适用于复杂主动脉弓部动脉瘤及穿透性溃疡的微创治疗，为全球首创无脑缺血一 体式弓部三分支重建解决方案。该产品将与主动脉弓部分支重建烟囱技术创新产品矩阵、主动脉弓部分 支重建原位开窗技术创新产品矩阵及SureCham单分支支架系统共同构成先健独特的主动脉弓部病变腔 内治疗整体解决方案。 消息面上，1月9日，由国家心血管病中心中国医学科学院阜外医院舒畅教授与先健科技联合研发的 Concave Supra一体式弓部三分支重建系统通过国家药品监督管理局批准，进入创新医疗器械特别审查 程序，即国家创新"绿色通道"。据悉，CS支架系统是先健第17款获批进入国家创新"绿色通道"的自主原 研创新产品。 ...

Group 1 - Northeast Securities expects a net profit of 1.477 billion yuan in 2025, a year-on-year increase of 69.06% [1] - Gansu Energy anticipates a net profit of 1.95 billion to 2.1 billion yuan in 2025, representing a year-on-year growth of 18.6% to 27.72% [2] - Ningbo Bank reports a projected net profit of 29.333 billion yuan in 2025, with an 8.13% year-on-year increase [3] Group 2 - Qianyuan Power forecasts a net profit of 567 million to 633 million yuan in 2025, indicating a year-on-year growth of 160% to 190% [5] - Batian Co. expects a net profit of 890 million to 980 million yuan in 2025, reflecting a year-on-year increase of 117.53% to 139.53% [6] - Tongfu Microelectronics anticipates a net profit of 1.1 billion to 1.35 billion yuan in 2025, with a year-on-year growth of 62.34% to 99.24% [7] Group 3 - Zhongyuan Nepe expects a net profit of 368 million to 428 million yuan in 2025, representing a year-on-year increase of 80.47% to 109.9% [8] - Huajin Co. predicts a net loss of 1.6 billion to 1.9 billion yuan in 2025, compared to a loss of 2.795 billion yuan in the previous year [9] - Xinghua Co. anticipates a net loss of 420 million to 560 million yuan in 2025, up from a loss of 380 million yuan in the previous year [4] Group 4 - Huayuan Holdings expects a net profit of 107 million to 118 million yuan in 2025, a year-on-year increase of 50.98% to 66.82% [12] - Taishan Petroleum forecasts a net profit of 130 million to 165 million yuan in 2025, indicating a year-on-year growth of 30.88% to 66.11% [13] - Jiuqi Software anticipates a net profit of 40 million to 60 million yuan in 2025, recovering from a loss of 156 million yuan in the previous year [21] Group 5 - Jin Fang Energy expects a net profit of 109 million to 143 million yuan in 2025, reflecting a year-on-year increase of 123.97% to 193.7% [16] - He Sheng New Materials anticipates a net profit of 152 million to 171 million yuan in 2025, representing a year-on-year growth of 55% to 75% [24] - Yuedong Microelectronics predicts a net loss of 340 million to 425 million yuan in 2025 [14] Group 6 - Aibo Medical plans to acquire at least 51% of Demai Medical, with an estimated valuation of the target company not exceeding 1 billion yuan [26] - Zhaoshang Shipping intends to build four 3000TEU container ships with a total investment of no more than 1.324 billion yuan [18] - Zhongtung High-tech's subsidiary has confirmed an increase in mineral resources, adding significant quantities of tungsten and other metals [27]

（记者 曾健辉） 每经头条（nbdtoutiao）——"一周干完一年的活"，一款AI编程工具让硅谷程序员集体"上瘾"！科技公 司CEO：一辈子钻研的技能被它一次性解决，让人兴奋又恐惧 每经AI快讯，创新医疗1月20日晚间发布公告称，创新医疗管理股份有限公司阮光寅董事持有公司股份 约154万股，占公司总股本的0.3492%，计划在本公告披露之日起15个交易日后的三个月内，以集中竞 价交易方式减持公司股份，合计减持数量不超过约39万股，即不超过公司总股本的0.0873%。 ...

人民财讯1月20日电，创新医疗（002173）1月20日公告，持股0.3492%的董事阮光寅拟减持公司不超 38.52万股，即不超公司总股本的0.0873% ...

格隆汇1月20日丨创新医疗(002173.SZ)公布，阮光寅董事持有公司股份1,540,987股，占公司总股本的 0.3492%，计划在本公告披露之日起15个交易日后的三个月内，以集中竞价交易方式减持本公司股份， 合计减持数量不超过385,200股，即不超过公司总股本的0.0873%。 ...

证券代码：002173 证券简称：创新医疗 公告编号：2026-003 创新医疗管理股份有限公司 关于董事减持股份的预披露公告 阮光寅董事保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 创新医疗管理股份有限公司（以下简称"公司"）阮光寅董事持有公司股份 1,540,987 股，占公司总股本的 0.3492%，计划在本公告披露之日起 15 个交易日 后的三个月内，以集中竞价交易方式减持本公司股份，合计减持数量不超过 385,200 股，即不超过公司总股本的 0.0873%。 公司于近日收到阮光寅董事提交的《股份减持计划告知函》。根据《上市公 司股东减持股份管理暂行办法》、《上市公司董事、监事和高级管理人员所持本公 司股份及其变动管理规则》、《深圳证券交易所上市公司自律监管指引第 18 号— —股东及董事、监事、高级管理人员减持股份》等有关规定，现将具体内容公告 如下： 一、股东的基本情况 1、股东名称：阮光寅 2、股东持有股份的数量、占公司总股本的比例：截至本公告披露日，阮光 寅持有公司股份 1, ...